Melissa Dodson
Acute Care · Long Beach, CANPI 1306204698
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,553 of the $11,770 with a category attached, or 72.7%. It is spread thinly across 46 manufacturers, the largest accounting for just 21.9%. 2025 is the largest year on record at $3,572, 3.1 times the $1,145 reported in 2021. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $31.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- AbbVie$2K
- Medtronic$1K
- Neurocrine Biosciences, Inc.$616
- AstraZeneca$533
- Biogen$530
- plus $4K from 40 others
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$2,98725%
- Food & beverage$8,55373%
- Education$2042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$2,365
- PERCEPT PC BRAINSENSE$864
- BRILINTA$125
- Duopa$122
How this compares
$11,770 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 21 | $23,219 |
| Nurtec OdtRimegepant Sulfate | 11 | $12,464 |
| Memantine Hcl | 168 | $6,106 |
| BrilintaTicagrelor | 14 | $6,010 |
| Rivastigmine | 37 | $5,748 |
| Gabapentin | 128 | $3,209 |
| Levetiracetam | 92 | $2,864 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 76 | $2,621 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 26 | $2,530 |
| Entacapone | 15 | $2,276 |
| Clobazam | 12 | $1,960 |
| Quetiapine Fumarate | 124 | $1,887 |
| Lacosamide | 32 | $1,646 |
| Oxcarbazepine | 23 | $1,637 |
| Lamotrigine | 40 | $1,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $85 | $23,21921 claims |
| PfizerNurtec Odt | $169 | $12,46411 claims |
| AstraZenecaBrilinta | $533 | $6,01014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Long Beach
- Cindy PetersLong Beach$7K
- Eunice ChanLong Beach$6K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.